BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 35983812)

  • 1. The Effectiveness of Prostate Imaging and Reporting and Data System Version 2 in the Diagnosis of Prostate Cancer with Screening Parameters Correlation.
    Arik ŞB; Güvenir D; Bozlar U; Taşar M; Turgut B
    Arch Esp Urol; 2022 Jun; 75(5):416-422. PubMed ID: 35983812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can Prostate Imaging Reporting and Data System Version 2 reduce unnecessary prostate biopsies in men with PSA levels of 4-10 ng/ml?
    Xu N; Wu YP; Chen DN; Ke ZB; Cai H; Wei Y; Zheng QS; Huang JB; Li XD; Xue XY
    J Cancer Res Clin Oncol; 2018 May; 144(5):987-995. PubMed ID: 29504080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate Health Index Density Outperforms Prostate-specific Antigen Density in the Diagnosis of Clinically Significant Prostate Cancer in Equivocal Magnetic Resonance Imaging of the Prostate: A Multicenter Evaluation.
    Chiu PK; Leow JJ; Chiang CH; Mok A; Zhang K; Hsieh PF; Zhu Y; Lam W; Tsang WC; Fan YH; Lin TP; Chan TY; Leung CH; Teoh JY; Chu PS; Zhu G; Ye DW; Wu HC; Tan TW; Tsu JH; Ng CF; Chiong E; Huang CY
    J Urol; 2023 Jul; 210(1):88-98. PubMed ID: 37036248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of prostate imaging reporting and data system (PI-RADS) score and prostate-specific antigen (PSA) density predicts biopsy outcome in prostate biopsy naïve patients.
    Washino S; Okochi T; Saito K; Konishi T; Hirai M; Kobayashi Y; Miyagawa T
    BJU Int; 2017 Feb; 119(2):225-233. PubMed ID: 26935594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In-Bore 3-T MR-guided Transrectal Targeted Prostate Biopsy: Prostate Imaging Reporting and Data System Version 2-based Diagnostic Performance for Detection of Prostate Cancer.
    Tan N; Lin WC; Khoshnoodi P; Asvadi NH; Yoshida J; Margolis DJ; Lu DS; Wu H; Sung KH; Lu DY; Huang J; Raman SS
    Radiology; 2017 Apr; 283(1):130-139. PubMed ID: 27861110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate imaging-reporting and data system version 2 in combination with clinical parameters for prostate cancer detection: a single center experience.
    Wang L; Luo Y; Liu T; Deng M; Huang X
    Int Urol Nephrol; 2023 Jul; 55(7):1659-1664. PubMed ID: 37171702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PSA density is complementary to prostate MP-MRI PI-RADS scoring system for risk stratification of clinically significant prostate cancer.
    Frisbie JW; Van Besien AJ; Lee A; Xu L; Wang S; Choksi A; Afzal MA; Naslund MJ; Lane B; Wong J; Wnorowski A; Siddiqui MM
    Prostate Cancer Prostatic Dis; 2023 Jun; 26(2):347-352. PubMed ID: 35523940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can the addition of clinical information improve the accuracy of PI-RADS version 2 for the diagnosis of clinically significant prostate cancer in positive MRI?
    Polanec SH; Bickel H; Wengert GJ; Arnoldner M; Clauser P; Susani M; Shariat SF; Pinker K; Helbich TH; Baltzer PAT
    Clin Radiol; 2020 Feb; 75(2):157.e1-157.e7. PubMed ID: 31690449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How to make clinical decisions to avoid unnecessary prostate screening in biopsy-naïve men with PI-RADs v2 score ≤ 3?
    Zhang Y; Zeng N; Zhang F; Huang Y; Tian Y
    Int J Clin Oncol; 2020 Jan; 25(1):175-186. PubMed ID: 31473884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Preliminary applicability evaluation of Prostate Imaging Reporting and Data System version 2 diagnostic score in 3.0T multi-parameters magnetic resonance imaging combined with prostate specific antigen density for prostate cancer].
    Zuo MZ; Zhao WL; Wei CG; Zhang CY; Wen R; Gu YF; Li MJ; Zhang YY; Wu JF; Li X; Shen JK
    Zhonghua Yi Xue Za Zhi; 2017 Dec; 97(47):3693-3698. PubMed ID: 29325321
    [No Abstract]   [Full Text] [Related]  

  • 11. Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies.
    Radtke JP; Wiesenfarth M; Kesch C; Freitag MT; Alt CD; Celik K; Distler F; Roth W; Wieczorek K; Stock C; Duensing S; Roethke MC; Teber D; Schlemmer HP; Hohenfellner M; Bonekamp D; Hadaschik BA
    Eur Urol; 2017 Dec; 72(6):888-896. PubMed ID: 28400169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate cancer gene 3 (PCA3) is of additional predictive value in patients with PI-RADS grade III (intermediate) lesions in the MR-guided re-biopsy setting for prostate cancer.
    Kaufmann S; Bedke J; Gatidis S; Hennenlotter J; Kramer U; Notohamiprodjo M; Nikolaou K; Stenzl A; Kruck S
    World J Urol; 2016 Apr; 34(4):509-15. PubMed ID: 26267808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deep Learning-Based T2-Weighted MR Image Quality Assessment and Its Impact on Prostate Cancer Detection Rates.
    Lin Y; Belue MJ; Yilmaz EC; Harmon SA; An J; Law YM; Hazen L; Garcia C; Merriman KM; Phelps TE; Lay NS; Toubaji A; Merino MJ; Wood BJ; Gurram S; Choyke PL; Pinto PA; Turkbey B
    J Magn Reson Imaging; 2024 Jun; 59(6):2215-2223. PubMed ID: 37811666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of PI-RADS version 2 and PI-RADS version 2.1 for the detection of transition zone prostate cancer.
    Tamada T; Kido A; Takeuchi M; Yamamoto A; Miyaji Y; Kanomata N; Sone T
    Eur J Radiol; 2019 Dec; 121():108704. PubMed ID: 31669798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Who can safely evade a magnetic resonance imaging fusion-targeted biopsy (MRIFTB) for prostate imaging reporting and data system (PI-RADS) 3 lesion?
    Kim M; Ryu H; Lee HJ; Hwang SI; Choe G; Hong SK
    World J Urol; 2021 May; 39(5):1463-1471. PubMed ID: 32696126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PI-RADS Version 2 Category on 3 Tesla Multiparametric Prostate Magnetic Resonance Imaging Predicts Oncologic Outcomes in Gleason 3 + 4 Prostate Cancer on Biopsy.
    Faiena I; Salmasi A; Mendhiratta N; Markovic D; Ahuja P; Hsu W; Elashoff DA; Raman SS; Reiter RE
    J Urol; 2019 Jan; 201(1):91-97. PubMed ID: 30577397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
    Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG
    BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lesion volume predicts prostate cancer risk and aggressiveness: validation of its value alone and matched with prostate imaging reporting and data system score.
    Martorana E; Pirola GM; Scialpi M; Micali S; Iseppi A; Bonetti LR; Kaleci S; Torricelli P; Bianchi G
    BJU Int; 2017 Jul; 120(1):92-103. PubMed ID: 27608292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient-related characteristics predict prostate cancers in men with PI-RADS 4-5 to further optimize the diagnostic performance of MRI.
    Xiang L; Ma S; Xu Y; Jiang L; Guo H; Liu H; Liu Y
    Abdom Radiol (NY); 2023 Dec; 48(12):3766-3773. PubMed ID: 37776336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can high b-value 3.0 T biparametric MRI with the Simplified Prostate Image Reporting and Data System (S-PI-RADS) be used in biopsy-naïve men?
    Wang G; Yu G; Chen J; Yang G; Xu H; Chen Z; Wang G; Bai Z
    Clin Imaging; 2022 Aug; 88():80-86. PubMed ID: 34243992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.